同仁堂2021年第三季度报告

艾媒舆情 | 2018上半年中国医药行业品牌形象感知与舆情应对数据分析报告

2017-2018年是医药改革的关键年，两票制、药品零加成、分级诊疗制度、医保目录更新等改革政策频出，迈入“快车道”，健康中国上升至国家战略层面。

艾媒咨询 | 2025年中国内地及香港地区花胶行业消费趋势白皮书

当前，中国花胶行业正处于需求扩容与产业升级的交织阶段。在内地，随着国民健康意识的深化，花胶从传统滋补品逐渐走入大众消费视野，消费场景从节庆送礼、产后调理向日常养生、轻食代餐延伸，年轻群体对这一品类的接受度显著提升。而香港地区，凭借其国际金融与贸易中心的地位，以及深厚的滋补养生文化底蕴，在花胶行业中占据独特位置。香港消费者对花胶品质与品类有着较高追求，推动着行业产品的精细化与高端化发展。同时，行业发展仍面临瓶颈：市场存在品类认知模糊、品质参差不齐的现象。供应链端则呈现传统渠道与新兴电商并行的格局，整体市场正从分散化的初级形态向规范化、细分化方向演进。
全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国内地及香港地区花胶行业消费趋势白皮书》数据显示，53.9%的消费者在购买花胶产品时关注“产品功效/营养价值”，其中养颜养肤（59.9%）、增强免疫力（47.8%）、补充/恢复精力（42.9%）等是消费者认为的花胶核心功效。女性食用花胶的主要场景有日常滋补（61.9%）、备孕期（27.9%）及孕期（27.2%），其中日常滋补主要为经期后调理身体。从地区差异来看，中国内地的花胶应用场景正从传统的产后恢复向日常滋补等场景延伸；而在中国香港，花胶已深度融入本土饮食与习俗，场景成熟且广泛。
艾媒咨询分析师认为，随着消费者健康需求的精细化与场景化升级，花胶行业正迎来产品形态与消费生态的深度重构。即食化、便携化产品将加速渗透日常消费场景，打破传统滋补品的使用局限。同时，中国内地及香港两地市场未来有望持续强化交流、互补优势，共同探索消费需求与市场新机。整个行业将从分散化竞争向品牌化、集约化发展转型，花胶也将从区域性滋补品向国民级健康食品迈进，成为连接传统滋补智慧与现代健康生活的标志性品类。
China’s fish-maw sector is now at the intersection of surging demand and industrial upgrading. On the mainland, deepening health awareness has moved fish maw from a niche tonic into the mainstream; consumption occasions have expanded from festival gifting and postpartum recovery to daily wellness and light-meal substitutes, with Gen-Z acceptance rising sharply. Hong Kong, leveraging its role as an international financial and trading hub and its long-standing tonic culture, occupies a unique position: propelling the market toward greater refinement and premiumization.Yet the industry remains constrained by legacy models. Products are still dominated by dried formats, carrying high entry barriers, while consumer knowledge is fragmented and quality uneven. Supply chains operate through both traditional channels and nascent e-commerce; the overall market is evolving from a fragmented, rudimentary state toward standardization and segmentation.
According to the latest White paper on the consumption trends of the fish maw industry in the Chinese mainland and Hong Kong region in 2025, released by iiMedia Research, 53.9% of buyers prioritize “product efficacy/nutritional value.”Top perceived benefits are beauty and skin nourishment (59.9%), immunity enhancement (47.8%), and energy replenishment/recovery (42.9%). Among women, the leading consumption scenarios are daily wellness (61.9%), primarily post-menstrual recuperation), pre-pregnancy preparation (27.9%), and pregnancy support (27.2%). Geographically, the mainland is shifting from postpartum recovery to broader daily wellness, whereas Hong Kong has fully woven fish maw into local cuisine and customs, yielding mature and diverse usage occasions.
Analysts at iiMedia believe that as health needs become more granular and scenario-specific, the sector is poised for deep restructuring of product formats and the consumer ecosystem. Ready-to-eat and portable offerings will rapidly penetrate everyday life, breaking the limitations of traditional tonics. Going forward, the mainland and Hong Kong markets are expected to strengthen interaction and complement each other, jointly exploring new demand and opportunities. The industry will transition from fragmented competition to branded, intensive development, and fish maw will evolve from a regional tonic into a national health food—an iconic category bridging traditional wellness wisdom and modern healthy living.

艾媒报告|2019-2020中国保健品行业研究报告

本报告研究涉及企业/品牌/案例：无限极，汤臣倍健，康宝莱，Swisse；其他提及企业/品牌：安利，东阿阿胶，合生元，完美，同仁堂，新时代健康，惠氏

iiMedia Research (艾媒咨询)数据显示，过去6年保健品行业市场规模保持两位数的增速，至2019年，市场规模约达2227亿元，2021年有望突破3300亿元。随着健康消费观念提升，养生需求从“银发一族”逐渐往“年轻一代”扩散。此外新兴科技与行业融合将推动产品和服务升级，为行业发展带来利好。消费者方面，超四成的受访者将产品品牌作为其购买时首要考虑因素，其中43.8%的消费者是自发购买保健品的，另外消费者对保健品行业的信心逐渐恢复，五成受访者看好保健品行业发展，超七成受访消费者认为保健品行业合规性有所提高。艾媒咨询分析师认为，目前保健品行业呈较好发展态势，但与此同时保健品行业同质化竞争激烈，在消费人群的扩大化、细分化的趋势下，企业需要通过加强品牌建设和精细化管理，提升产品及服务品质，更好适应市场变化。

According to the data of iiMedia Research，in the past 6 years, the market size of the health products industry has maintained a double-digit growth rate. By 2019, the market size will be approximately 222.7 billion yuan, which is expected to exceed 330 billion yuan in 2021. With the upgrading concept of healthy consumption, the demand for health care has gradually spread from the “silver-haired people” to the “younger generation”. In addition, the integration of emerging technologies and industries will promote the improving of products and services, bringing benefits to the development of the industry. In terms of consumers, over 40% of the interviewees regard product brand as their primary consideration when purchasing. 43.8% of consumers purchase health products spontaneously. In addition, consumer confidence in the health care product industry has gradually recovered. Nearly 50% of the respondents are optimistic about the development of the health care product industry, and over 70% of the consumers believe that the compliance of the health care product industry has improved. Besides, consumer confidence in the health care product industry has gradually recovered. Nearly 50% of the respondents are optimistic about the development of the health care product industry, and over 70% of the interviewed consumers believe that the compliance of the health care product industry has improved. iiMedia Consulting analysts believe that the current health care industry is showing a good development trend, but at the same time, under the trend of expanding and subdividing consumer groups ,the homogenization of the health care industry is fiercely competitive. Enterprises need to enhance the quality of products and services by strengthening brand building and refined management to better adapt to market changes.

艾媒报告|2019-2021年中国中药材用户调研及延伸市场研究报告

本报告研究涉及企业/品牌/案例：同仁堂，片仔癀，东阿阿胶，太极集团，胡庆余堂，同仁牛黄清心丸，黄芪颗粒，雷氏丹参片，云峰气血口服液，太极五子衍宗丸，太极生力雄丸，仲景左归丸，一笑堂龟甲壳，白云山复方丹参片，天士力养血清脑颗粒，白云山夏桑菊颗粒，白云山板蓝根颗粒

随着居民消费水平的提升和健康保健意识的增强，总体健康需求在扩大，进而推动中医药市场的发展，2018年中国中药材市场规模达1246亿元，同比增长22.40%，预计到2024年，中药材市场规模将达2004亿元。
iiMedia Research（艾媒咨询）调查显示，2019年接近五成受访者购买过中药材，滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛，中医药产业链不断扩展延伸，并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场，建设中药大健康产业，如植物提取物、保健食品、中药化妆品等，已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.

（以下为节选页，完整版共88页）

艾媒咨询｜2023-2024年中国中药材行业大数据及商业趋势研究报告

随着居民消费水平的提升和健康保健意识的增强，总体健康需求在扩大，进而推动中医药市场的发展。iiMedia Research（艾媒咨询）数据显示，2022年中国中药材市场规模达到1708亿元，预计2024年将超过2000亿元，中药材市场规模扩大前景可观。

艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告

本报告研究涉及企业/品牌/案例：白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业，培力控股,盛实百草,芍花堂,亳药千草,汇群中药

国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research（艾媒咨询）调查显示，有49%的受访用户倾向中医药治疗，与西药基本持平。2018年中国中药材市场规模达1246亿元，同比增长22.40%，在巨大的需求驱动下，中药材种植面积扩大，药材产量将会持续增长。

中药材主要包括上游种植、养殖市场，中游流通市场和下游销售市场三大环节。目前，中药饮片和中成药生产是中药产业的核心，主要包括中药加工，包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面，行业销售收入增速分别在2016和2018年触底回升，华润三九、中国中药、红日药业等上市公司表现良好；中药配方颗粒方面，2006-2016年，中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%，中药配方颗粒或将成为中药饮片加工行业应用广泛的产品；中成药方面，随着国家医改政策的推行，中成药消费需求趋于合理，中成药产量开始回落，但仍处于一个比较高的产量水平，云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。

Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well.

艾媒咨询|2021Q1中国保健品及NMN市场研究报告

本报告研究涉及企业/品牌/案例：汤臣倍健,健合集团,同仁堂,雅本化学,金达威

iiMedia Research (艾媒咨询)数据显示，随着国家人均GDP的提升，消费者在保健食品消费理念和消费意愿上都发生了根本性的转变，保健食品在消费属性上将逐渐从可选消费品向必选消费品转变，预计2021年中国保健品市场规模将增至2708亿元。在新冠疫情影响下，国民保健意识加速觉醒，居民消费观念升级，对保健品需求增加，为保健品行业带来长期利好。此外，市场对抗衰老产品需求的提升推动了NMN成分产品的走俏，预计到2023年将会以近70.25%的增速攀升至270.13亿元。
As the data of iiMedia Research showed, with the increase of the country's per capita GDP, consumers' consumption concept and willingness of health food have undergone fundamental changes. The consumption attribute of health food will gradually change from optional consumer goods to compulsory consumer goods. It is estimated that the market scale of health food in China will increase to 270.8 billion yuan in 2021. Under the influence of COVID-19, the awareness of national health care has been speeded up, the consumption concept of residents has been upgraded, and the demand for health products has increased, which has brought long-term benefits to the health care products industry. In addition, the increasing demand for anti-aging products in the market has promoted the popularity of NMN products, which is expected to rise to 27.013 billion yuan with a growth rate of nearly 70.25% by 2023.

ST辅仁2021年第三季度报告

仁和药业：2021年第三季度报告